A prospective natural history study of inclusion body myositis: implications for clinical trials

Neurology. 2001 Aug 14;57(3):548-50. doi: 10.1212/wnl.57.3.548.


Eleven patients with untreated inclusion body myositis (IBM) were prospectively studied during a 6-month period that included muscle strength, lean body mass, and muscle mass measurements. There was an overall quantifiable mean decline in percent of predicted normal muscle strength of 4% from baseline in a 6-month period, but one third of patients showed no change or slight improvements in strength. Short-term treatment trials in IBM will require large numbers of patients to detect slowing, arrest, or even slight improvement in muscle strength.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Clinical Trials as Topic*
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myositis, Inclusion Body / physiopathology*